Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

Rosa Ahn; Vinay Prasad

doi:10.1007/s10557-018-6830-x

Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

Rosa Ahn, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	633-635
Number of pages	3
Journal	Cardiovascular Drugs and Therapy
Volume	32
Issue number	6
DOIs	https://doi.org/10.1007/s10557-018-6830-x
State	Published - Dec 1 2018

ASJC Scopus subject areas

Pharmacology
Cardiology and Cardiovascular Medicine
Pharmacology (medical)

Access to Document

10.1007/s10557-018-6830-x

Cite this

@article{fef4c641a2a64dfeb89f04bd4304dd64,

title = "Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?",

author = "Rosa Ahn and Vinay Prasad",

year = "2018",

month = dec,

day = "1",

doi = "10.1007/s10557-018-6830-x",

language = "English (US)",

volume = "32",

pages = "633--635",

journal = "Cardiovascular Drugs and Therapy",

issn = "0920-3206",